Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518216 · ClinicalTrials.gov registry record · NA
Neural Mechanisms of Treatment Response to ADAPT
A NA study of Anxiety and Functional Abdominal Pain Syndrome, sponsored by Michigan State University.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03518216: Completed NA study of Anxiety and Functional Abdominal Pain Syndrome, sponsored by Michigan State University.
NCT03518216 is a NA study of Anxiety and Functional Abdominal Pain Syndrome that has completed, run by Michigan State University. The registered enrollment target is 49 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03518216, a NA study of Anxiety and Functional Abdominal Pain Syndrome, has completed, sponsored by Michigan State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
Complex functional abdominal pain disorders (FAPD) with co-occurring anxiety are highly prevalent in children, can be very disabling, and are not responsive to currently available treatments. This research aims to better understand the neural mechanisms involved in a promising nonpharmacological treatment for FAPD to ultimately guide the development of more targeted treatment approaches for afflicted youth.
Primary Outcome
Changes in functional connectivity will be examined using the Blood Oxygenation Level Dependent (BOLD) effect
Conditions Studied
Interventions
- BEHAVIORAL ADAPT
Study Locations (1)
Michigan
- Michigan State University - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
What the finished NCT03518216 record still lists
NCT03518216 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which ADAPT is the first listed.
NCT03518216 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03518216 about?
NCT03518216 is a clinical study titled "Neural Mechanisms of Treatment Response to ADAPT". Complex functional abdominal pain disorders (FAPD) with co-occurring anxiety are highly prevalent in children, can be very disabling, and are not responsive to currently available treatments. This research aims to better understand the neural mechanisms involved in a promising nonpharmacological tre...
What is the current status of trial NCT03518216?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2018-07-03. Estimated completion is 2024-12-31.
What conditions does trial NCT03518216 study?
This clinical trial studies the following conditions: Anxiety, Functional Abdominal Pain Syndrome.
What interventions are being tested in trial NCT03518216?
The interventions under investigation include: ADAPT (BEHAVIORAL).
Who is sponsoring clinical trial NCT03518216?
This trial is sponsored by Michigan State University, which has 120 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03518216 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03518216's enrollment target sits among peer trials
49 256th of 364 higher than 109 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI